Employers and benefit consultants weigh the list-price reset

Novo Nordisk announced on February 24, 2026, that it will lower the U.S. list price, or wholesale acquisition cost, of Wegovy, Ozempic and Rybelsus to $675 per month, effective January 1, 2027 ^[2]. The company said this represents cuts of roughly 50% for Wegovy and about 35% for Ozempic from current list prices, and that the change applies to all doses of the three semaglutide products ^[2]. Novo Nordisk said the move is meant to help patients whose out-of-pocket costs are tied to list price, "such as individuals with high-deductible health plans or co-insurance benefit designs," according to Jamey Millar, the company's executive vice president of U.S. operations ^[2]. The new price does not change direct-to-patient, self-pay prices through NovoCare Pharmacy or similar programs ^[2].

Benefits consulting firm Mercer told employers the timing is not a coincidence. The January 1, 2027 start date lines up with the Medicare maximum fair price for these drugs, which also takes effect that day, and with the expected launch of new competing weight-loss products from Novo Nordisk and other manufacturers ^[1]. Mercer said an oral product could reach the market as soon as April 2026, and that three more injectable weight-loss drugs, including one from a manufacturer new to the category, could launch in 2027 ^[1].

For employers, the practical effect is more complicated than a simple price cut. Mercer said Novo Nordisk is expected to offset the lower list price by reducing the rebates it pays back to health plans and pharmacy benefit managers, meaning employers' net costs after rebates are likely to stay roughly the same ^[1]. In fact, because rebates may shrink more than the price does for some contracts, employers could end up paying a slightly larger share of total drug costs even as members pay less ^[1].

Who benefits depends on plan design. Members with coinsurance, where they pay a percentage of the drug's cost, or those in high-deductible plans who pay list price until they hit their deductible, could see real reductions at the counter ^[1][2]. Members with flat-dollar copays, which are common in many employer plans, are less likely to notice a difference, since their share is usually set by contract rather than tied directly to list price ^[1].

Mercer also said the lower list price could change the math behind coverage rules. Strategies like requiring lifestyle programs, limiting coverage to higher-risk groups, or applying BMI cutoffs can reduce the rebate value plans receive; with a smaller price-to-rebate gap, those tradeoffs may shrink, potentially giving some employers more room to loosen restrictions ^[1]. It could also make it more feasible for employers to cover newer semaglutide indications, such as reducing cardiovascular risk, without having to also cover the broader obesity indication just to preserve rebate eligibility ^[1].

Why it matters for patients

The list price is what shows up before insurance discounts and rebates are applied, so it directly affects patients who pay coinsurance, are in a deductible period, or lack insurance coverage for these drugs ^[1][2]. Those patients could see lower costs starting in 2027. But patients with standard employer coverage and flat copays may not notice any change, since insurers and employers, not patients, mostly absorb list-price shifts through the rebate system ^[1]. The direct-to-consumer self-pay price, often used by patients without insurance coverage for weight loss drugs, is not changing under this announcement ^[2].

What happens next

The new $675 list price takes effect January 1, 2027, the same day Medicare's negotiated maximum fair price for these drugs begins ^[1]. Mercer said employers negotiating 2027 pharmacy benefit contracts should factor in the change now, and warned that some retail pharmacies may temporarily thin their inventory of the affected products as the price change approaches, which could cause brief delays for patients filling prescriptions late in 2026 ^[1]. A new oral GLP-1 product could launch as early as April 2026, and additional injectable competitors are expected in 2027, developments Mercer said could add further pricing pressure across the category ^[1].